 |
|
|
 |
FDA Approves Gleevec For Leukemia Treatment
The Food and Drug Administration today announced the approval of Gleevec (imatinib mesylate, also known as STI-571), a promising new oral treatment for patients with chronic myeloid leukemia (CML) -- a rare life-threatening form of cancer. FDA reviewed the marketing application for Gleevec (formerly spelled Glivec) in less than three months under its "accelerated approval" regulations. more
|
|
New Treatment May Increase Survival In Children With Medulloblastoma
An ongoing study at St. Jude Children's Research Hospital indicates that a new treatment protocol could increase survival rates for some pediatric brain cancers to 80 percent for high-risk and 90 percent for standard-risk. The study appears in the 15 May 2001 issue of the Journal of Clinical Oncology. more
|
|
|
|
Prescribing Information: Gleevec (Imatinib Mesylate)
Gleevec (imatinib mesylate), formerly known as STI571 and Glivec, has gone through a rapid development process. Novartis Pharmaceuticals Corporation saw the potentially significant patient benefits of Gleevec in early testing and took every step to ensure that Gleevec was made available to as many patients as possible and as quickly as possible. As a result, the overall time to make Gleevec available for prescription was drastically reduced. Get the full prescribing information for the drug in today's issue of Vidyya. more
|
|
Coalition Successful In Halting Spread Of Vancomycin-Resistant Enterococcus (VRE)
A coalition comprised of healthcare facilities, state and local health departments in the Siouxland Region of Iowa, Nebraska, and South Dakota, the Indian Health Service, and the Centers for Disease Control and Prevention (CDC) has been successful in combating the spread of vancomycin-resistant enterococcus (VRE), according to data published in the 10 May 2001 issue of the New England Journal of Medicine. more
|
|
CDC Report Regarding Selected Public Health Topics Affecting Women's Health
Prevention research helps us to understand conditions and diseases and who they affect; develop and implement effective strategies and programs to reduce disease and promote health; and develop policies and recommendations that strengthen systems and programs at local, state, and national levels. This particular publication focuses on birth defects and human immunodeficiency virus infection/acquired immunodeficiency syndrome (HIV/AIDS), two preventable causes of death and disability. The articles focus on programs in several states that are designed to reduce disease and assess disease trends. The primary messages are not new, but need to be reinforced. more
|
|
|
